Study: CFS Linked to Latent EBV Replication; polyDNA Recommends Gene-Eden-VIR Against Latent Epstein Barr Virus and Resulting Fatigue
Rochester, NY (PRWEB) March 30, 2014 -- Research shows that the Epstein-Barr virus (EBV) may cause Chronic Fatigue Syndrome (CFS) (1). “Chronic fatigue syndrome, or CFS, is a debilitating and complex disorder characterized by profound fatigue that is not improved by bed rest and that may be worsened by physical or mental activity.” (See the CDC, last updated on May 16, 2012) (2). Importantly, researchers found that patients with CFS have more viral proteins associated with a latent EBV infection than normal, healthy people (1). polyDNA recommends that individuals with CFS ask their doctors for an EBV blood test. If positive, speak to the doctor about Gene-Eden-VIR. This natural antiviral targets the latent EBV, and was recently proven to reduce mental and physical fatigue in a post-marketing clinical study that followed FDA guidelines.
“CFS onset typically goes along with a viral illness… (and)…for many years, researchers have suspected EBV to be involved in CFS. A hallmark of CFS is chronic activation of the immune system, which can be triggered by infections… (1).” Study authors found no evidence for an active EBV infection in CFS patients. Instead, there was evidence for a latent infection with the Epstein Barr Virus. “We had no evidence of lytic replication as we could neither detect EBER DNA in plasma nor BZLF-1 RNA in PBMCs. Thus, our findings suggest a higher level of latency-associated replication in CFS patients (1).”
“Most scientists and physicians believe that latent viruses cause no pathologies or symptoms. The FDA even states on its website: ‘Some viruses, however, can enter a state known as latency in which the virus is not being replicated. In the latent state, the virus does not cause disease.’ As a result, current standard medical practices don’t target latent viruses. In contrast to this belief, the Microcompetition with Foreign DNA theory, proposed by Hanan Polansky in 2003, describes how viruses, during their latent phase, can cause a chronic disease.” (See Pharmacology & Pharmacy, from March 2014) (3).
Thus, there is much scientific evidence for a latent viral cause of CFS. This is an important fact to understand since many CFS patients report “feelings of anger, guilt, anxiety, isolation and abandonment (4),” because of a misconception that CFS patients may be “faking” their symptoms. However, CFS symptoms, including disabling fatigue, and a latent viral infection, are very real.
As the CDC notes, “Chronic fatigue syndrome, or CFS, is a devastating and complex disorder. People with CFS have overwhelming fatigue and a host of other symptoms that are not improved by bed rest and that can get worse after physical activity or mental exertion. They often function at a substantially lower level of activity than they were capable of before they became ill (4).”
“The fatigue of CFS is accompanied by characteristic illness symptoms lasting at least 6 months. These symptoms include: increased malaise (extreme exhaustion and sickness) following physical activity or mental exertion, problems with sleep, difficulties with memory and concentration, persistent muscle pain, joint pain (without redness or swelling), headache, tender lymph nodes in the neck or armpit, (and a) sore throat (4).”
There are no FDA approved treatments for CFS. However, a recent post-marketing clinical study, conducted by the Center for the Biology of Chronic Disease (CBCD), found that Gene-Eden-VIR decreased feelings of general, physical, and mental fatigue (3). As the authors of the study concluded, “Gene-Eden-VIR safely decreased the feeling of general, physical, and mental fatigue in individuals infected with a latent virus (like EBV). Since most individuals are infected with a latent virus, health care practitioners should recommend Gene-Eden-VIR as a first line treatment for fatigue (3).”
This is the second time that a peer reviewed medical journal published a paper reporting a clinical study on Gene-Eden-VIR’s, patent protected, natural formula. The first paper, entitled “Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study” was published in September 2013 and can be found at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.UzQEv6iSz90.
To view the entire paper on Gene-Eden-VIR and fatigue, visit: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.UzQC5KiSz90.
For more information on Gene-Eden-VIR please visit the product’s official website at: http://www.gene-eden-vir.com.
We invite the media to contact us for interviews at: note (AT) buy-gene-eden.com or phone 585-250-9999. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
References:
(1) Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome. Published in January 2014.
http://www.ncbi.nlm.nih.gov/pubmed/24454857
(2) CDC - Chronic Fatigue Syndrome (CFS). Last updated on May 16, 2012.
http://www.cdc.gov/cfs/
(3) Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory. Published in March 2014.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.UzVBp6iSz90
(4) CDC - Chronic Fatigue Syndrome (CFS). Last updated on May 14, 2012.
http://www.cdc.gov/cfs/symptoms/index.html
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.
Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]
Share this article